AXSM 250117 45.00C (AXSM250117C45000) Stock Options, News & Quotes

US OptionsDetailed Quotes

AXSM250117C45000

Watchlist

47.30
-0.20-0.42%

15min DelayClose Jan 17 16:00 ET

47.30High47.30Low

Intraday

5D
Daily

News

Those Who Invested in Axsome Therapeutics (NASDAQ:AXSM) Three Years Ago Are up 280%
Simply Wall St07:05 ET
Optimistic Buy Rating for Axsome Therapeutics Driven by Auvelity's Strong Market Performance and Potential
TipRanks02:45 ET · Ratings
Needham's Top Stocks for 2025: AX, CYBR, CART and More
Seeking AlphaJan 14 11:20 ET
Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?
Zacks Jan 14 08:20 ET
TD Cowen Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Moomoo NewsJan 14 01:33 ET · Ratings
Express News | Axsome Therapeutics Shares Are Trading Higher After the Company Reported Preliminary Q4 and FY2024 Net Product Revenue. Additionally, Truist Securities Raised Its Price Target on the Stock From $150 to $180 While Maintaining a Buy Rating
BenzingaJan 13 12:14 ET

Comments

Clintzilla

Oct 12, 2024 14:13

$Axsome Therapeutics (AXSM.US)$ wonder what the insitutional ownership was when it went from 2 to 110 lol

Vincenttpc

Sep 25, 2024 08:07

$Axsome Therapeutics (AXSM.US)$ why the sudden drop?

Meltyy

Mar 18, 2024 03:21

FDA Development Paths

$Pfizer (PFE.US)$ $Novo-Nordisk A/S (NVO.US)$ $Axsome Therapeutics (AXSM.US)$ $Macrogenics (MGNX.US)$
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...

Meltyy

Mar 4, 2024 03:54

🎯 Ph 3 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3
$Sellas Life Sciences (SLS.US)$ Phase 3
$Aquestive Therapeutics (AQST.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phase 3
$Novocure (NVCR.US)$ Phase 3
$Johnson & Johnson (JNJ.US)$ Phase 3

Meltyy

Feb 26, 2024 00:34

4 Bio Readouts To Watch This Qtr

1. $Annovis Bio (ANVS.US)$
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics (AXSM.US)$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics (GTHX.US)$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics (CRNX.US)$
• Ph 3 data (PATHFND...